KPTI — Karyopharm Therapeutics Inc.

Karyopharm Therapeutics (KPTI) Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Q4 2025 Total Revenue: $34.1 million, up 11.8% year-over-year.
• Full Year 2025 Total Revenue: $146.1 million, a slight increase from 2024.
• U.S. XPOVIO Net Product Revenue: $32.1 million for Q4 2025 (up 9.6% YoY) and $114.9 million for the full year (up 1.9% YoY).
• Gross to Net Provisions: 26.9% for Q4 and 31.2% for the full year.
• Operating Loss: Improved by approximately 43% in Q4 2025 and 24% for the full year compared to 2024.
• Net Loss: $102.2 million in Q4 ($5.71 per share) and $196 million for the full year ($17.93 per share), largely due to noncash items.
• Cash Position: $64.1 million at year-end, down from $109.1 million in 2024.

2. Strategic Updates and Business Highlights

• Selinexor's Position: Established in multiple myeloma; expected to expand into myelofibrosis and endometrial cancer.
• Upcoming Trials: Top-line data from the Phase III SENTRY trial for myelofibrosis is expected in March 2026, with a focus on combination therapy with ruxolitinib.
• Endometrial Cancer: Phase III XPORT-EC-042 trial data is anticipated in mid-2026, targeting a specific patient population with limited treatment options.
• Commercial Strategy: Continued emphasis on positioning XPOVIO in both community and academic settings, with plans to leverage existing relationships for rapid market entry in myelofibrosis.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: Total revenue expected between $130 million to $150 million, with U.S. XPOVIO net product revenue projected at $115 million to $130 million.
• Expense Management: R&D and SG&A expenses anticipated to be in the range of $230 million to $245 million.
• Cash Runway: Current liquidity is expected to fund operations into Q2 2026, aligning with key clinical milestones.

4. Bad News, Challenges, or Points of Concern

• Declining Cash Position: Significant decrease in cash reserves from the previous year raises concerns about funding future operations.
• Increased Interest Expense: Higher debt levels and interest rates have contributed to increased financial strain.
• Competitive Pressures: Novartis is advancing its own myelofibrosis treatment, which could impact Karyopharm's market position if successful.
• Regulatory Uncertainty: While the company is optimistic about upcoming data, any negative results could hinder future growth and market acceptance.

5. Notable Q&A Insights

• Confidence in Upcoming Data: Management expressed strong confidence in the efficacy and safety of the 60 mg dose of selinexor based on prior Phase I data.
• Market Need: There is a significant unmet need in myelofibrosis, with current therapies not adequately addressing patient symptoms.
• Regulatory Feedback: KOLs indicated that while symptom improvement is important, spleen volume reduction (SVR) will be a primary treatment driver for acceptance.
• Combination Therapy Strategy: The company is positioned as the first potential combination therapy in frontline myelofibrosis, which could set a new standard of care if data is positive.

Overall, Karyopharm is at a pivotal moment with significant clinical milestones approaching, but it faces challenges related to cash flow, competition, and the need for successful trial outcomes to support its growth strategy.